{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:57:53Z","timestamp":1772240273480,"version":"3.50.1"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1001\/jamadermatol.2018.4836","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T15:55:07Z","timestamp":1548345307000},"page":"283","source":"Crossref","is-referenced-by-count":5,"title":["Targeted Treatment of <i>TREX1<\/i> Chilblain Lupus and Other Interferonopathies\u2014Taming T REX"],"prefix":"10.1001","volume":"155","author":[{"given":"William","family":"Damsky","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett A.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"9","key":"ded180024r1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"7","key":"ded180024r2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11926-018-0748-y","article-title":"An update on autoinflammatory diseases: interferonopathies.","volume":"20","author":"Davidson","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"ded180024r3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases.","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"ded180024r4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class.","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ded180024r5","article-title":"Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation [published online January 23, 2019].","author":"Zimmermann","journal-title":"JAMA Dermatol"},{"issue":"7","key":"ded180024r6","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"ded180024r7","article-title":"Efficacy of JAK1\/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency","author":"Briand","journal-title":"Ann Rheum Dis"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamadermatology\/article-pdf\/155\/3\/283\/17393075\/jamadermatology_damsky_2019_ed_180024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T12:33:31Z","timestamp":1552480411000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.4836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.4836","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}